Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02485652
Title Phase II Trial of HM61713 for the Treatment of >= 2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hanmi Pharmaceutical Company Limited
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN | AUS


No variant requirements are available.